Smart Therapeutic Strategy of pH-Responsive Gold Nanoparticles for Combating Multidrug Resistance,Particle & Particle Systems Characterization

当前位置： X-MOL 学术 › Part. Part. Syst. Charact. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Smart Therapeutic Strategy of pH-Responsive Gold Nanoparticles for Combating Multidrug Resistance
Particle & Particle Systems Characterization ( IF 2.7 ) Pub Date : 2021-06-12 , DOI: 10.1002/ppsc.202100073
Muhammad U. Farooq ₁ , Muhammad Y. Naz ₂ , Muhammad I. Hussain ₃ , Shazia Shukrullah ₂ , Mohamed M. Makhlouf ₄

Affiliation

As several multi-target drug delivery approaches are successfully identified through preclinical screening, their clinical success is often hampered by challenges such as poor circulation stability, dissimilarities in the pharmacokinetics of different drugs, as well as targeting inefficiency. Gold nanoparticles (AuNPs) are adopted as promising nanocarriers in the co-delivery of multiple therapeutic drugs for combination therapy. The pH-responsive AuNPs are synthesized and incorporated with multiple chemotherapeutic drugs, such as doxorubicin and bleomycin. Such structures can work as drug carriers to treat cervical carcinoma by adopting a quality by design approach. The designed nanocarrier is characterized by adopting a range of physicochemical and morphological techniques. In vitro drug release and cytotoxicity of optimized nanocarriers are assessed to cervical tumor epithelial cells. The results highlight the notable advantages of colloidal AuNPs, including sustained drug release, therapeutic agent delivery with high stability, and biocompatibility for more effective treatment of cervical carcinoma. Furthermore, by improving the biodistribution and/or bioavailability profiles, it is believed that the two-in-one approach may therefore give evidence on the fate of co-loaded nanocarrier as a promising trajectory for successful clinical translation against ovarian carcinoma to achieve maximum therapeutic synergy for an individual patient.

中文翻译：

用于对抗多药耐药性的 pH 响应金纳米颗粒的智能治疗策略

由于通过临床前筛选成功确定了几种多靶点药物递送方法，它们的临床成功往往受到诸如循环稳定性差、不同药物的药代动力学差异以及靶向效率低下等挑战的阻碍。金纳米粒子 (AuNPs) 被用作有前途的纳米载体，用于联合治疗的多种治疗药物的共同递送。pH 响应的 AuNPs 被合成并与多种化疗药物结合，如阿霉素和博来霉素。通过采用质量源于设计的方法，这种结构可以作为药物载体来治疗宫颈癌。设计的纳米载体的特点是采用了一系列物理化学和形态学技术。评估优化的纳米载体对宫颈肿瘤上皮细胞的体外药物释放和细胞毒性。结果突出了胶体金纳米粒子的显着优势，包括药物持续释放、治疗剂递送稳定性高以及生物相容性，可更有效地治疗宫颈癌。此外，通过改善生物分布和/或生物利用度曲线，相信二合一方法可以证明共载纳米载体的命运是成功临床转化卵巢癌以实现最大治疗效果的有希望的轨迹。对个别患者的协同作用。具有高稳定性和生物相容性的治疗剂递送，可更有效地治疗宫颈癌。此外，通过改善生物分布和/或生物利用度曲线，相信二合一方法可以证明共载纳米载体的命运是成功临床转化卵巢癌以实现最大治疗效果的有希望的轨迹。对个别患者的协同作用。具有高稳定性和生物相容性的治疗剂递送，可更有效地治疗宫颈癌。此外，通过改善生物分布和/或生物利用度曲线，相信二合一方法可以证明共载纳米载体的命运是成功临床转化卵巢癌以实现最大治疗效果的有希望的轨迹。对个别患者的协同作用。

更新日期：2021-07-19

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11